Candel Therapeutics (CADL) EPS (Weighted Average and Diluted): 2021-2023
Historic EPS (Weighted Average and Diluted) for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to -$0.38.
- Candel Therapeutics' EPS (Weighted Average and Diluted) fell 123.53% to -$0.38 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.30, marking a year-over-year decrease of 103.12%. This contributed to the annual value of -$1.74 for FY2024, which is 32.82% down from last year.
- Per Candel Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.38 for Q4 2023, which was down 31.03% from -$0.29 recorded in Q3 2023.
- Over the past 5 years, Candel Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.51 during Q4 2021, and registered a low of -$0.69 during Q3 2021.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.23, with a median of -$0.30 in 2023.
- As far as peak fluctuations go, Candel Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 64.10% in 2022, and later crashed by 900.00% in 2023.
- Quarterly analysis of 3 years shows Candel Therapeutics' EPS (Weighted Average and Diluted) stood at $0.51 in 2021, then slumped by 133.33% to -$0.17 in 2022, then tumbled by 123.53% to -$0.38 in 2023.
- Its EPS (Weighted Average and Diluted) was -$0.38 in Q4 2023, compared to -$0.29 in Q3 2023 and -$0.33 in Q2 2023.